Xiaohuan Xia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaohuan Xia has a total of 411 co-authors. Here are the top co-authors by number of shared publications:
- Jialin Charles Zheng
Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China
39 shared publications Yi Wang
Translational Research Center, Shanghai Yangzhi Rehabilitation Hospital Affiliated to Tongji University School of Medicine, Shanghai, China
26 shared publicationsCongcong Li
Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
10 shared publicationsJie Zhu
Center for Translational Neurodegeneration and Regenerative Therapy, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
10 shared publicationsLu Ding
Department of Anesthesiology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
9 shared publicationsShu Zhao
Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China
9 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Nature Aging
- p. 1-22
Mitochondria-derived extracellular vesicles mediate Alzheimer’s disease pathology through transmitting microglial Ggt1
Extracellular vesicles (EVs) can modify pathological progression in Alzheimer’s disease (AD), the most common neurodegenerative disease in older adults, by spreading pathogenic factors. However, the function of mitovesicles (mtVs)—a recently identified subset of EVs—in AD remain unknown. Here we show that release of mtVs is enriched in brain tissue from patients with AD and 5×FAD mice. Administration of 5×FAD mouse brain-derived mtVs (ADmtVs) induced AD-like behavioral and pathological changes in wild-type mice and accelerated disease progression of AD mice. Moreover, the release of mtVs was regulated by mitochondrial respiratory metabolism, and blocking the release of mtVs significantly alleviated AD-like phenotypes. Proteomic analysis identified Ggt1 as a highly enriched protein in ADmtVs. Inhibiting Ggt1 expression and activity mitigated AD-like phenotypes of 5×FAD mice and delayed ADmtV-induced disease progression, suggesting Ggt1 as a pathological cargo of ADmtVs. Our findings highlight the pathological roles of mtVs in AD and highlight mtVs and Ggt1 as potential therapeutic targets.
- 10 November 2026
- Published by Springer Nature in Nature Aging
- p. 1-22
Open AccessMitochondria-derived extracellular vesicles mediate Alzheimer’s disease pathology through transmitting microglial Ggt1
Extracellular vesicles (EVs) can modify pathological progression in Alzheimer’s disease (AD), the most common neurodegenerative disease in older adults, by spreading pathogenic factors. However, the function of mitovesicles (mtVs)—a recently identified subset of EVs—in AD remain unknown. Here we show that release of mtVs is enriched in brain tissue from patients with AD and 5×FAD mice. Administration of 5×FAD mouse brain-derived mtVs (ADmtVs) induced AD-like behavioral and pathological changes in wild-type mice and accelerated disease progression of AD mice. Moreover, the release of mtVs was regulated by mitochondrial respiratory metabolism, and blocking the release of mtVs significantly alleviated AD-like phenotypes. Proteomic analysis identified Ggt1 as a highly enriched protein in ADmtVs. Inhibiting Ggt1 expression and activity mitigated AD-like phenotypes of 5×FAD mice and delayed ADmtV-induced disease progression, suggesting Ggt1 as a pathological cargo of ADmtVs. Our findings highlight the pathological roles of mtVs in AD and highlight mtVs and Ggt1 as potential therapeutic targets.
- Open Access
- 22 October 2026
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 46 (1) , 39
Mitochondrial dysfunction in microglia: a novel perspective of depression pathogenesis
Major depressive disorder is a prevalent psychiatric disease that is closely linked to chronic low-grade neuroinflammation, which is primarily driven by mi
- 22 October 2026
- Published by Springer Nature in Inflammation and Regeneration
- Vol. 46 (1) , 39
Open AccessMitochondrial dysfunction in microglia: a novel perspective of depression pathogenesis
Major depressive disorder is a prevalent psychiatric disease that is closely linked to chronic low-grade neuroinflammation, which is primarily driven by mi
- Open Access
- 1 September 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-21
Targeting microglial glutaminase 1 protects against ferroptosis-driven cognitive impairment in perioperative neurocognitive disorders
Perioperative neurocognitive disorders (PND) are common neurological complications in elderly surgical patients, for which effective mechanism-based therapies remain lacking. This study identifies ferroptosis, an iron-dependent lipid peroxidation-driven cell death, as a key pathological process in PND, and pharmacological inhibition of ferroptosis with ferrostatin-1 significantly ameliorated cognitive deficits in a surgery and anesthesia-induced mouse model of PND. Moreover, accumulation of glutamate has been observed in the brains of PND mice, which competitively inhibits the neuronal cystine/glutamate antiporter system Xc - (via SLC7A11) to trigger glutathione depletion and ferroptotic cell death. Excessive glutamate production and release are driven by hyperexpression of glutamate-producing enzyme glutaminase 1 (GLS1) in activated microglia via STAT1-dependent transcriptional activation. Pharmacological inhibition of GLS1 with the selective inhibitors CB839 and BPTES suppressed ferroptosis, preserved synaptic plasticity, and improved cognitive performance in PND mice, indicating GLS1 as a potential therapeutic target of PND. Notably, elevated plasma GLS1 levels in PND patients correlated negatively with cognitive test scores ( R 2 = 0.479, p < 0.001) and exhibited moderate diagnostic value across two independent cohorts (AUCs = 0.77 and 0.84), underscoring its clinical relevance as a potential biomarker. Collectively, our findings establish microglial GLS1 as a critical mediator of ferroptosis in PND and highlight its dual promise as a therapeutic target and diagnostic indicator.
- 1 September 2026
- Published by Springer Nature in Cell Death & Differentiation
- p. 1-21
Open AccessTargeting microglial glutaminase 1 protects against ferroptosis-driven cognitive impairment in perioperative neurocognitive disorders
Perioperative neurocognitive disorders (PND) are common neurological complications in elderly surgical patients, for which effective mechanism-based therapies remain lacking. This study identifies ferroptosis, an iron-dependent lipid peroxidation-driven cell death, as a key pathological process in PND, and pharmacological inhibition of ferroptosis with ferrostatin-1 significantly ameliorated cognitive deficits in a surgery and anesthesia-induced mouse model of PND. Moreover, accumulation of glutamate has been observed in the brains of PND mice, which competitively inhibits the neuronal cystine/glutamate antiporter system Xc - (via SLC7A11) to trigger glutathione depletion and ferroptotic cell death. Excessive glutamate production and release are driven by hyperexpression of glutamate-producing enzyme glutaminase 1 (GLS1) in activated microglia via STAT1-dependent transcriptional activation. Pharmacological inhibition of GLS1 with the selective inhibitors CB839 and BPTES suppressed ferroptosis, preserved synaptic plasticity, and improved cognitive performance in PND mice, indicating GLS1 as a potential therapeutic target of PND. Notably, elevated plasma GLS1 levels in PND patients correlated negatively with cognitive test scores ( R 2 = 0.479, p < 0.001) and exhibited moderate diagnostic value across two independent cohorts (AUCs = 0.77 and 0.84), underscoring its clinical relevance as a potential biomarker. Collectively, our findings establish microglial GLS1 as a critical mediator of ferroptosis in PND and highlight its dual promise as a therapeutic target and diagnostic indicator.
- Open Access
- 10 March 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1) , 164
Transcranial magnetic stimulation mitigates perioperative neurocognitive disorders by regulating the function of the glymphatic system
The incidence of perioperative neurocognitive disorders (PND) increase with age, especially within those countries facing great challenge of aging populati
- 10 March 2026
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 24 (1) , 164
Open AccessTranscranial magnetic stimulation mitigates perioperative neurocognitive disorders by regulating the function of the glymphatic system
The incidence of perioperative neurocognitive disorders (PND) increase with age, especially within those countries facing great challenge of aging populati
- Open Access
- 14 October 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (42) , 37186-37205
N -Acetylcysteine-Capped TLQP21-Containing Au Nanocages Alleviate Depression in Mice
Major depressive disorder (MDD) is the most prevalent neuropsychiatric disorder globally. Promising therapies for MDD are urgently needed due to the limited effectiveness, delayed efficacy, and non-negligible side effects of current treatments. Oxidative stress and neuroinflammation have been recognized as key contributors to MDD. Here, we developed an antioxidant N-acetylcysteine (NAC)-capped Au nanocage (TNNC) that entrapped VGF-derived peptide TLQP21 with neuro-immunomodulatory effects. Once internalized by cells suffering from oxidative stress, NAC was consumed, and TLQP21 was released from TNNC. TNNC administration alleviated MDD-like behaviors of the chronic unpredictable mild stress (CUMS)-exposed mice and effectively relieved oxidative stress in the brains. Moreover, TLQP21 in TNNC inhibits the activation, excessive synaptic pruning, and inflammatory responses of microglia through targeting the complement C1q receptor (C1qR) and complement C3a receptor 1 (C3aR1). This work provides a bioinspired strategy to target multiple pathogenic factors in one nanoparticle for the intervention of MDD and other diseases.
- 14 October 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (42) , 37186-37205
Open AccessN -Acetylcysteine-Capped TLQP21-Containing Au Nanocages Alleviate Depression in Mice
Major depressive disorder (MDD) is the most prevalent neuropsychiatric disorder globally. Promising therapies for MDD are urgently needed due to the limited effectiveness, delayed efficacy, and non-negligible side effects of current treatments. Oxidative stress and neuroinflammation have been recognized as key contributors to MDD. Here, we developed an antioxidant N-acetylcysteine (NAC)-capped Au nanocage (TNNC) that entrapped VGF-derived peptide TLQP21 with neuro-immunomodulatory effects. Once internalized by cells suffering from oxidative stress, NAC was consumed, and TLQP21 was released from TNNC. TNNC administration alleviated MDD-like behaviors of the chronic unpredictable mild stress (CUMS)-exposed mice and effectively relieved oxidative stress in the brains. Moreover, TLQP21 in TNNC inhibits the activation, excessive synaptic pruning, and inflammatory responses of microglia through targeting the complement C1q receptor (C1qR) and complement C3a receptor 1 (C3aR1). This work provides a bioinspired strategy to target multiple pathogenic factors in one nanoparticle for the intervention of MDD and other diseases.
- 9 September 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1669-1685
The X-Age Project to construct a Chinese aging clock
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.
- 9 September 2025
- Published by Springer Nature in Nature Aging
- Vol. 5 (9) , 1669-1685
The X-Age Project to construct a Chinese aging clock
The global surge in the population of people 60 years and older, including that in China, challenges healthcare systems with rising age‐related diseases. To address this demographic change, the Aging Biomarker Consortium (ABC) has launched the X-Age Project to develop a comprehensive aging evaluation system tailored to the Chinese population. Our goal is to identify robust biomarkers and construct composite aging clocks that capture biological age, defined as an individual’s physiological and molecular state, across diverse Chinese cohorts. This Perspective outlines the core objectives, methodological framework and key deliverables of the X-Age Project, including cohort recruitment, standardized sample collection, multimodal data acquisition and clock model development. By integrating interdisciplinary expertise, we aim to provide a practical and scalable platform for understanding aging complexity and heterogeneity, early detection of accelerated aging and evaluation of aging interventions.
- Open Access
- 10 April 2025
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 52 (6) , e70040
Plasma IL4 Levels Linked to Pulmonary Hypertension Severity and Outcome
Background: The anti‐inflammatory cytokine interleukin‐4 (IL4) has been recognised as a protective factor in various cardiovascular events, yet its prognostic value in patients with pulmonary hypertension (PH) remains unclear. The study aimed to measure the levels of plasma IL4 in patients with PH and to explore their potential association with disease risk and outcomes.Methods: In this observational study, we analysed the levels of plasma IL4 in 766 PH patients and 191 healthy controls in Shanghai Pulmonary Hospital from October 2009 to January 2024. To establish the correlations between plasma IL4 levels and the risk and outcomes of PH, all patients were followed up from June 2013 to June 2024. The Spearman correlation test was employed to evaluate the relationships between IL4 and right heart catheterisation parameters among patients with PH. Receiver operating characteristic (ROC) curves were generated to evaluate the diagnostic performance of IL4 for PH. The Cox proportional hazards models and Kaplan–Meier survival curves were used to assess the prognostic value of IL4 levels. Logistic regression analysis was performed to predict PH incidence. A nomogram was constructed to predict mortality, and its clinical utility was validated using decision curve analysis (DCA).Results: Plasma IL4 levels were significantly decreased in patients with PH compared with controls (p < 0.001), as well as in different PH groups (p < 0.05 for all). The logistic regression analyses indicated that the lower IL4 levels were associated with the high risk of PH (OR = 0.79, 95% CI: 0.716–0.872; p < 0.001). IL4 levels correlated inversely with NT‐proBNP (r = −0.10, p < 0.05) and mPAP (r = −0.01, p < 0.05), and positively with CI (r = 0.12, p < 0.05) and PaSaO2 (r = 0.11, p < 0.05), indicating an association with disease severity. Kaplan–Meier analysis revealed that patients with IL4 ≥ 2.8774 pg/mL had a 3‐year cumulative survival rate of 91.28%, compared with 82.83% for those with IL4 < 2.8774 pg/mL (log–rank p = 0.007). Cox regression confirmed IL4 as an independent predictor of survival (HR = 0.810, 95% CI: 0.660–0.993; p = 0.043). A diagnostic model combining IL4, 6MWD and NT‐proBNP demonstrated good prognostic value (AUC = 0.692, p < 0.0001).Conclusions: Plasma IL4 levels were significantly decreased in patients with PH, exhibiting a negative correlation with disease severity; furthermore, lower IL4 levels may serve as a prognostic indicator of poor outcomes in patients with PH.
- 10 April 2025
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 52 (6) , e70040
Open AccessPlasma IL4 Levels Linked to Pulmonary Hypertension Severity and Outcome
Background: The anti‐inflammatory cytokine interleukin‐4 (IL4) has been recognised as a protective factor in various cardiovascular events, yet its prognostic value in patients with pulmonary hypertension (PH) remains unclear. The study aimed to measure the levels of plasma IL4 in patients with PH and to explore their potential association with disease risk and outcomes.Methods: In this observational study, we analysed the levels of plasma IL4 in 766 PH patients and 191 healthy controls in Shanghai Pulmonary Hospital from October 2009 to January 2024. To establish the correlations between plasma IL4 levels and the risk and outcomes of PH, all patients were followed up from June 2013 to June 2024. The Spearman correlation test was employed to evaluate the relationships between IL4 and right heart catheterisation parameters among patients with PH. Receiver operating characteristic (ROC) curves were generated to evaluate the diagnostic performance of IL4 for PH. The Cox proportional hazards models and Kaplan–Meier survival curves were used to assess the prognostic value of IL4 levels. Logistic regression analysis was performed to predict PH incidence. A nomogram was constructed to predict mortality, and its clinical utility was validated using decision curve analysis (DCA).Results: Plasma IL4 levels were significantly decreased in patients with PH compared with controls (p < 0.001), as well as in different PH groups (p < 0.05 for all). The logistic regression analyses indicated that the lower IL4 levels were associated with the high risk of PH (OR = 0.79, 95% CI: 0.716–0.872; p < 0.001). IL4 levels correlated inversely with NT‐proBNP (r = −0.10, p < 0.05) and mPAP (r = −0.01, p < 0.05), and positively with CI (r = 0.12, p < 0.05) and PaSaO2 (r = 0.11, p < 0.05), indicating an association with disease severity. Kaplan–Meier analysis revealed that patients with IL4 ≥ 2.8774 pg/mL had a 3‐year cumulative survival rate of 91.28%, compared with 82.83% for those with IL4 < 2.8774 pg/mL (log–rank p = 0.007). Cox regression confirmed IL4 as an independent predictor of survival (HR = 0.810, 95% CI: 0.660–0.993; p = 0.043). A diagnostic model combining IL4, 6MWD and NT‐proBNP demonstrated good prognostic value (AUC = 0.692, p < 0.0001).Conclusions: Plasma IL4 levels were significantly decreased in patients with PH, exhibiting a negative correlation with disease severity; furthermore, lower IL4 levels may serve as a prognostic indicator of poor outcomes in patients with PH.
- Open Access
- 5 December 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1510746
miR-185-5p regulates the proliferation and differentiation of neural stem/progenitor cells
Background: MicroRNAs (miRNAs) have emerged as an essential regulator of the cell fate commitment of neural stem/progenitor cells (NPCs), although the impacts of certain miRNAs on NPCs remain vague. The aim of this study is to investigate the regulatory effects of miR-185-5p on the cell fate commitment of NPCs.Methods: We investigated the impact of miR-185-5p on the proliferation and differentiation capacities of primary NPCs by manipulating the expression of miR-185-5p using specific mimics and inhibitors. The effects of miR-185-5p on NPCs was confirmed in vivo through stereotactic injection of miR-185-5p antagonists to the brains of mice at postnatal day 1 (P1).Results: The expression levels of miR-185-5p kept increasing in the differentiation process of NPCs in vivo and in vitro. Perturbation of miR-185-5p’s function showed that miR-185-5p inhibited NPCs’ proliferation and promoted embryonic NPCs to differentiate more favorably to the glial lineage. We then validated the anti-proliferation and pro-glial roles of miR-185-5p using NPCs isolated from P1 mouse brains. In vivo study further showed enlarged NPCs pools and inhibited gliogenesis in the brains of P1 mice after animals received antagomir-185-5p.Conclusion: Our study suggests miR-185-5p as an important regulator for the proliferation and glial fate commitment of NPCs.
- 5 December 2024
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 12, 1510746
Open AccessmiR-185-5p regulates the proliferation and differentiation of neural stem/progenitor cells
Background: MicroRNAs (miRNAs) have emerged as an essential regulator of the cell fate commitment of neural stem/progenitor cells (NPCs), although the impacts of certain miRNAs on NPCs remain vague. The aim of this study is to investigate the regulatory effects of miR-185-5p on the cell fate commitment of NPCs.Methods: We investigated the impact of miR-185-5p on the proliferation and differentiation capacities of primary NPCs by manipulating the expression of miR-185-5p using specific mimics and inhibitors. The effects of miR-185-5p on NPCs was confirmed in vivo through stereotactic injection of miR-185-5p antagonists to the brains of mice at postnatal day 1 (P1).Results: The expression levels of miR-185-5p kept increasing in the differentiation process of NPCs in vivo and in vitro. Perturbation of miR-185-5p’s function showed that miR-185-5p inhibited NPCs’ proliferation and promoted embryonic NPCs to differentiate more favorably to the glial lineage. We then validated the anti-proliferation and pro-glial roles of miR-185-5p using NPCs isolated from P1 mouse brains. In vivo study further showed enlarged NPCs pools and inhibited gliogenesis in the brains of P1 mice after animals received antagomir-185-5p.Conclusion: Our study suggests miR-185-5p as an important regulator for the proliferation and glial fate commitment of NPCs.
- Open Access
- 15 December 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Microglial glutaminase 1 mediates chronic restraint stress-induced depression-like behaviors and synaptic damages
- 15 December 2023
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 8 (1) , 1-4
Open AccessMicroglial glutaminase 1 mediates chronic restraint stress-induced depression-like behaviors and synaptic damages